GreenLight Biosciences, Inc., a Medford, MA-based bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications, raised $50m in the first closing of its latest funding round.
The round was led by S2G Ventures, Baird Capital and Blue I/O, with participation from Continental Grain Company, Tao Capital Partners and Alexandria Venture Investments.
The company intends to use the funds for the expansion of the discovery and development capabilities in multiple segments that bring a vast array of bio-performance products, including agricultural bio-control products and human and animal vaccines and therapeutics.
Led by Andrey Zarur, Co-Founder/CEO, GreenLight develops RNA products for plant and life science applications, and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, and plant protection. The team is currently focused on the discovery and development of RNA-based products for agriculture and human health.
The company has established partnerships with leading corporations and academic institutions and continues to collaborate with these parties to accelerate the development of a portfolio of bio-performance candidates for plant and life sciences.
GreenLight has Plant Sciences R&D operations in RTP, NC and St. Louis, MO.